dichlororibofuranosylbenzimidazole has been researched along with Leukemia, Erythroblastic, Acute in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Friend virus-transformed murine erythroleukemia (MEL) cells are a useful system for studying the regulation of erythroid growth and differentiation." | 1.29 | RNA polymerase II inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) causes erythroleukemic differentiation and transcriptional activation of erythroid genes. ( Barth, D; Hensold, JO; Stratton, CA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hensold, JO | 1 |
| Barth, D | 1 |
| Stratton, CA | 1 |
| Mukherjee, R | 1 |
| Molloy, GR | 1 |
2 other studies available for dichlororibofuranosylbenzimidazole and Leukemia, Erythroblastic, Acute
| Article | Year |
|---|---|
RNA polymerase II inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) causes erythroleukemic differentiation and transcriptional activation of erythroid genes.
Topics: Animals; Cell Differentiation; Cell Division; Chromosomal Proteins, Non-Histone; Dichlororibofuranos | 1996 |
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription of the beta-hemoglobin gene in vivo at initiation.
Topics: Animals; Cell Line; Cell Nucleus; Dichlororibofuranosylbenzimidazole; Genes; Hemoglobins; Kinetics; | 1987 |